Compare Archer-Daniels-Midland Co (ADM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Sana Biotechnology Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.81 (market cap $37.69B), while Sana Biotechnology Inc trades at $3.94 (market cap $1.15B). The key difference: Archer-Daniels-Midland Co is far larger — about 32.8× Sana Biotechnology Inc's market cap, and Archer-Daniels-Midland Co pays a 2.66% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ADM | SANA | |
|---|---|---|
Market Cap | $37.69B | $1.15B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $5.92 |
52-Week Low | $53.54 | $2.68 |
Enterprise Value | $47.72B | $1.12B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
SANA Biotechnology trades at $3.97, down 1.0% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative ROE and ROA, while analyst consensus is strongly bullish with 82% buy ratings. Recent news highlights clinical data presentations and a $69 million share sale via an ATM facility in May 2026.
Outlook remains speculative with high investor optimism driven by clinical progress, but significant financial losses and cash burn pose risks. Upside depends on successful drug development, while downside risks include funding needs and trial setbacks. The stock offers high-risk, high-reward potential for biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
